Huntington's Disease Treatment Market Size & Share, by Drugs (Tetrabenazine, Deutetrabenazine, Other Drugs); Type; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

North America Market Analysis

North America held the largest market share in 2024 and is estimated to account for a 34.8% revenue share by 2037 owing to increasing cases of Huntington’s disease in the region. For instance, in September 2023, it was reported that between 2010 and 2012, North America had 1.21 per 100,000 person-years in HD cases. The data highlights a slight growth between 2012 to 2022 compared to the previous study in 2012 indicating a growing need for HD treatment in North America. Additionally, strong research and development investments in the region is poised to increase the market’s growth during the forecast period.

U.S. accounted for the largest share in the regional market in North America. The market in U.S. is growing due to the rising cases of HD diagnosis and the increasing demand for treatment. For instance, the Huntington’s Disease Society of America estimated in 2024, around 41,000 symptomatic patients in the U.S. that require treatment and more than 200,000 at risk of inheriting the disease. Additionally, U.S. has been proactive in spreading awareness on the disease and building a robust framework for HD treatment. For instance, the FDA has already approved two drugs, i.e., Austedo and Xenazine for management of HD symptoms and is pending stamp of approval on other drugs such as Pridopidine (Proof-HD), SOM3355, AMT-130, etc.

Canada is projected for a robust growth during the forecast period. The huntington’s disease treatment market growth is attributed to rising cases of HD in Canada and the growing demands for treatment and care. The Huntington’s Society of Canada estimates 1 in 7000 people in Canada to be diagnosed with HD and 1 in 5500 people to be at risk of the disease. Canada has been proactive in increasing diagnosis tests for HD. For instance, genetic testing for HD has been available in Canada since 1993 and has the efficacy has improved considerably in current times. Additionally, government support in the region for HD treatment boosts the market’s growth. For instance, in September 2021, the Huntington Society of Canada (HSC) introduced a long-term program to train neurologists in HD treatment. Such initiatives boost HD care and treatment

Europe Market Analysis

Europe is poised to register the fastest growth during the forecast period owing to growing cases of huntington’s disease and rising demands for treatment and care. HD prevalence is higher in people of European descent as per studies which increases the vulnerability in Europe, and positions the increase in demand for HD treatments. For instance, in August 2023, it was reported that HD prevalence ranged from 3 to 7 per 100,000 persons among European ancestry. Additionally, investments in HD research in Europe fuels the market’s rapid rise.

Germany is leading the huntington’s disease treatment market share in Europe due to a rising prevalence of HD cases and identification of people who may be at risk of inheriting the HD gene. For instance, German Center for Neurodegenerative Diseases (DZNE) estimates around 10,000 people to be affected by HD symptoms in Germany in 2024 and around 30,000 people to be at risk of carrying the gene. Demands for gene identification therapies to detect people at risk and effective treatment to manage chorea is driving the market in the country. New therapeutic cares are being researched to assist patients diagnosed with HD and support families caring for patients with HD.

France is estimated to increase its huntington’s disease treatment market share during the forecast period owing to rising diagnosis of HD. For instance, the Paris Brain Institute estimated around 18,000 people in France afflicted with Huntington’s disease and out of those, 6000 are exhibiting symptoms while 12000 carriers of the huntingtin gene remain asymptomatic. The market in France is boosted by the clinical trials and approvals of new drugs in Europe which positions market players to boost the revenue share by serving as distributors of new treatment methods. For instance, in September 2024, Prilenia’s Pridopidine for HD treatment was accepted for European marketing authorization review.

APAC Market Analysis

The Asia Pacific huntington’s disease treatment market is projected to register a rapid growth during the forecast period. The market in APAC is comparatively niche and is exhibiting signs of growth owing to rising awareness on Huntington’s disease leading to an increase in diagnosis. APAC also accounts for a significantly high number of population and administrating precision care for HD treatment opens opportunities for the key market players. Despite low prevalence of HD compared to North America and Europe, the increase rate of gene testing and awareness is expected to increase HD diagnosis percentage across APAC.

India accounts for a large share of the APAC market. The huntington’s disease treatment market growth in India is attributed to growing push for research on HD. In August 2024, it was reported that an estimated 7 in 1,00,000 people have Huntington’s disease. Additionally, every child of a parent diagnosed with HD has 50% chance of inheriting the affected gene which makes the population at risk higher.

India also accounts for the largest population in the world; hence, the cases of undiagnosed HD can be comparatively larger. In August 2024, HD patients, caregivers, and doctors submitted a referendum to the Union Health Ministry of India to include HD as a rare disease and make amendments to the National Policy of Rare Disease (NPRD). HD’s acceptance as a rare disease will open greater investments on research and improve HD care in the region.

China has a growing revenue share in the APAC huntington’s disease treatment market. The market in China is relatively niche compared to North America and Europe but the high population rate and growing investments in improving accessibility and quality of healthcare is poised to lead a stable market growth. In December 2023, the Economic Burden of Huntington’s Disease in China published a report that highlight 269 individuals with HD in China across various ages who are having financial troubles due to long-term HD care. China has a robust healthcare system with almost 95% of the population covered by 2020; assisting HD treatment costs.

Additionally, insurance coverage enables more people to actively seek HD treatment. Despite the low prevalence of HD in China, the pharmaceutical ecosystem in the country is robust and poised to offer HD treatment solutions globally that can boost the market’s growth. For instance, in March 2020, China approved the use of Austedo for managing HD related chorea and in February 2024, Jiangsu Nhwa and Teva announced a strategic partnership to improve patient access to Austedo in China.

South Korea is an emerging huntington’s disease treatment market with a rising prevalence of HD in the past decade. For instance, in January 2023, a paper published on NLM studied the number of cases in South Korea between 2010 and 2019. As per the findings, new HD cases in South Korea increased by almost a 1000 in 2019 and the number of people seeking HD treatment each year also increased, i.e., 144 in 2010 and 453 in 2019. The rising cases of HD and the increasing number of people seeking HD treatment is boosting the market in South Korea and by the end of 2037, the revenue share is estimated to increase.